One Step Closer to Affordable HIV Drug–Resistance Test By Martha Henry Harvard recently entered into a licensing agreement with Aldatu Biosciences for exclusive use of the PANDAA technology. Using PANDAA, Aldatu, a biotech start-up based at LabCentral in Cambridge, is developing a rapid HIV drug-resistance test for patients failing first-line antiretroviral therapy (ART).
Aldatu Licenses Technology from Harvard
